WO2005049057A1 - Use of cassia sophera linn. for treating diabetes - Google Patents

Use of cassia sophera linn. for treating diabetes Download PDF

Info

Publication number
WO2005049057A1
WO2005049057A1 PCT/CN2003/000995 CN0300995W WO2005049057A1 WO 2005049057 A1 WO2005049057 A1 WO 2005049057A1 CN 0300995 W CN0300995 W CN 0300995W WO 2005049057 A1 WO2005049057 A1 WO 2005049057A1
Authority
WO
WIPO (PCT)
Prior art keywords
effect
weeks
treating diabetes
drinking
group
Prior art date
Application number
PCT/CN2003/000995
Other languages
French (fr)
Chinese (zh)
Inventor
Xingbo Feng
Original Assignee
Xingbo Feng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xingbo Feng filed Critical Xingbo Feng
Priority to PCT/CN2003/000995 priority Critical patent/WO2005049057A1/en
Priority to AU2003304545A priority patent/AU2003304545A1/en
Priority to CNA2003801102572A priority patent/CN1764466A/en
Publication of WO2005049057A1 publication Critical patent/WO2005049057A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482Cassia, e.g. golden shower tree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • mangosteen and its extract in medicine for treating diabetes and improving symptoms thereof
  • the invention belongs to the field of medicinal use of traditional Chinese medicine.
  • Anemone (Cassia sophera Li dish.), A medicinal plant, Cassia spp.
  • Amaranth also known as Amaranth Cassia, is flat, non-toxic, and has a sweet taste. It has the effect of removing phlegm and thirst, making people sleepless, and regulating the effect. It is also known as Antipyretics. Alcoholic extracts from the leaves of Mang Mangosteen have the effect of relaxing the small intestine and bronchial smooth muscle of guinea pigs.
  • the purpose of the present invention is to prepare a medicament for treating diabetes and improving its symptoms by using mangosteen and its water extract.
  • the water extraction method is as follows:
  • Frying method Water is used as the solvent, and the effective ingredients are extracted by heating and boiling. Generally, it must be extracted 2-4 times, and the amount of solvent is generally 6-20 times the amount of awn.
  • Immersion method Cold soaking or warm soaking of amaranth for a large number of solvents, and after the ingredients are dissolved and equilibrated, the extraction solution is directly released.
  • Ultrasonic extraction method After soaking the awns, put them into ultrasonic waves together with the solvent, and use the effect of ultrasound to dissolve the awns. ,
  • Microwave extraction method Put the awn in the microwave together with the solvent, and use the microwave to polarize the molecules to dissolve the components.
  • the oral or gastrointestinal administration is safe.
  • oral administration it can be administered in any conventional form, such as Sanqi! ], Granules, tablets, capsules, pills, solutions, suspensions, syrups, buccal tablets, sublingual tablets, etc .;
  • the drug when administered parenterally, it can take any conventional form, such as injections (such as Intravenous injection), ointments, suppositories, transdermal administration, inhalants, etc.
  • the medicament prepared by the present invention for treating diabetes and improving its symptoms is composed of ramie or its water extract together with solid or liquid excipients.
  • the solid or liquid excipients used herein are well known in the art, Here are some specific examples.
  • Powder is an internal powder, and its excipients are lactose, starch, dextrin, calcium carbonate, synthetic or natural aluminum sulfate, magnesium oxide, magnesium stearate, sodium bicarbonate, dry Yeast, etc .
  • the excipients of the solution are water, glycerol, propylene glycol, monosyrup, ethanol, ethylene glycol, polyethylene glycol, sorbitol, etc .
  • the excipients of the ointment can be fatty oil, lanolin, petrolatum , Glycerin, beeswax, paraffin wax, liquid paraffin, resin, high-grade wax, etc.
  • the dosage of effective substance can be changed according to the way of taking, the age and weight of the patient and the severity of the disease and other similar factors.
  • the oral dose is: 10.0-15.0mg / kg, twice daily. / kg, once a day.
  • the medicine of the invention has better effects of lowering blood sugar, treating diabetes and improving symptoms. detailed description
  • test examples include pharmacodynamic tests and clinical efficacy observation tests.
  • Test example 1 Effect of burdock extract on hyperglycemic animal model in Wistar rats 1.1 Test materials
  • Drugs Mang Mang extract provided by the Research Institute of New Drugs, Institute of Regenerative Medicine, Jilin University, batch number: 20010708; Xiaoke pills are produced by Guangzhou No. 1 Chinese Medicine Factory, approval number: (1994) No. 11146.
  • JPS-III fast blood glucose tester produced by Beijing Yicheng Bioelectronic Technology Co., Ltd.
  • Wistar rats After the introduction of Wistar rats from the Animal Department of Jilin University, they were bred in the animal room of the Basic Medical College of Jilin University at room temperature 22-25 ° C, humidity 30-60%, feed composition: cornmeal 39%, bean cake noodle 25 ° /. , Wheat bran noodles 14%, sorghum noodles 10%, bone meal 2.5%, fish meal 5%, yeast 3.5%, and additives 1%.
  • Correction page 100 male and female rats in the normal range and in good condition were tested, and 10 rats were left as the normal control group.
  • 90 Wistar rats were modeled with streptozotocin STZ at 0.054 g / kg.
  • the vegetarian STZ was formulated into a 2.0% solution with a 0.05 mol / L citric acid solution pH 4.5, and is now used.
  • rats were injected with streptozotocin STZ solution once intraperitoneally according to their weight.
  • the blood glucose was measured, and a blood glucose level of greater than 10 mmol / L was established as a model.
  • P ⁇ 0.001 a significant difference
  • Fifty-four hyperglycemic model animals were randomly divided into five groups, with 10 to 11 animals in each group.
  • the groups are: normal control group, model group, Xiaoke Wan group 2.0g / kg, which is equivalent to 4 times the clinical dosage; mango extract large dose group 0.62g / kg, medium dose group 0.31g / kg, low dose group 0.15g / kg, equivalent to 8, 4, or 2 times the clinical dosage.
  • the model group was given 10 ml / kg of water, and each administration group was given 10 ml / kg of test solution. Gavage is administered around 9am every day for four consecutive weeks. Blood glucose and body weight are measured weekly, and the dose is calculated once based on the new weight. Animals were sacrificed after the fourth week of administration, blood tests were performed for blood routine, blood biochemical indicators, blood rheology and insulin content, and pancreas were taken for histopathological examination. The results obtained by each group are represented by the mean () ⁇ standard deviation (S), and the results are compared with the model group to perform a t-test between the groups to determine their significance.
  • S standard deviation
  • Table 1 Effect of Mangman extract on blood glucose value (mmol / L) in hyperglycemic model rats ( ⁇ ⁇ s) Normal control group ⁇ Model group Xiaoke Wan group Medium dose group Small dose group 3 ⁇ 4 Group 10ml / kg 2. Og / kg 0.62g / kg 0.31g / kg 0.15g / kg
  • the diabetic patients drink the invention the longer the drinking time, the more obvious the effect, that is, drinking for one week is basically ineffective, drinking for two weeks shows a hypoglycemic effect, drinking for three weeks has a significant hypoglycemic effect, and drinking for four weeks is extremely significant .
  • the 23 diabetes patients drinking the present invention in Table 1 were divided into two groups: those who had been sick for more than 5 years as a group, and those who had been sick for less than 4 years as a group. Statistical analysis was performed, and the results were ⁇
  • Table 8 shows the analysis of drinking effects for patients under 4 years of illness.
  • Amaranth has a significant effect on reducing blood sugar in patients with diabetes.
  • the disease is shorter (less than 4 years) longer than the time (more than 5 years).
  • Mangosteen water extract 2.0g, water 1000ml, mixed into 100 bottles, each 100ml, containing 20mg of mangosteen extract.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention relates to the use of Cassia sophera Linn. and its extract for treating diabetes and ameliorating the symptoms of diabetes. The invention relates to the use of traditional Chinese medicine. The invention's medicine has an excellent blood glucose lowering effect. The invention's medicine will show an effect in two weeks of administration and show a significant effect in four weeks. So Cassia sophera Linn. And its extract can be used as desirable medicines for treating diabetes and ameliorating the symptoms of diabetes.

Description

茳芒及其提取物在治疗糖尿病及改善其症状药物中的应用 技术领域  Application of mangosteen and its extract in medicine for treating diabetes and improving symptoms thereof
本发明属于中药的药物用途领域。  The invention belongs to the field of medicinal use of traditional Chinese medicine.
背景技术 Background technique
茳芒 (Cassia sophera Li皿.), 药用植物, 豆科苏木亚科决明属。 据《中药大辞典》中记载: "茳芒, 又称茳芒决明, 性平, 无毒, 味 甘滑。 具有除痰止渴, 令人不睡, 调中的功效。 又称其为解热药。 茳芒 叶的醇提物有松弛豚鼠小肠、支气管平滑肌的作用。"本发明中是指的是 茳芒子。  Anemone (Cassia sophera Li dish.), A medicinal plant, Cassia spp. According to the "Traditional Chinese Medicine Dictionary": "Amaranth, also known as Amaranth Cassia, is flat, non-toxic, and has a sweet taste. It has the effect of removing phlegm and thirst, making people sleepless, and regulating the effect. It is also known as Antipyretics. Alcoholic extracts from the leaves of Mang Mangosteen have the effect of relaxing the small intestine and bronchial smooth muscle of guinea pigs.
发明内容 Summary of the invention
本发明的目的就是应用茳芒及其水提取物制备治疗糖尿病及改善其 症状的药物。  The purpose of the present invention is to prepare a medicament for treating diabetes and improving its symptoms by using mangosteen and its water extract.
其水提物采用水提方法为:  The water extraction method is as follows:
1.煎煮法: 以水为溶媒, 加热煮沸提取有效成分, 一般须提取 2-4 次, 溶媒用量一般为茳芒量的 6- 20倍。  1. Frying method: Water is used as the solvent, and the effective ingredients are extracted by heating and boiling. Generally, it must be extracted 2-4 times, and the amount of solvent is generally 6-20 times the amount of awn.
2.渗漉法: 为茳芒经冷浸泡或温浸泡后, 以适当温度的溶媒, 流经 茳芒, 以溶出茳芒之成分。  2. Infiltration method: After cold soaking or warm soaking, the mango is passed through the mango with a solvent at an appropriate temperature to dissolve the components of the mango.
3.浸渍法: 为大量溶媒冷浸泡或温浸泡茳芒, 待成分溶出平衡后, 直接放出提取液。  3. Immersion method: Cold soaking or warm soaking of amaranth for a large number of solvents, and after the ingredients are dissolved and equilibrated, the extraction solution is directly released.
4.超声提取法: 为茳芒经浸泡后, 与溶媒一起置超声波中, 利用超 声波的效应, 使茳芒成分溶出。 、  4. Ultrasonic extraction method: After soaking the awns, put them into ultrasonic waves together with the solvent, and use the effect of ultrasound to dissolve the awns. ,
1 1
更正页(细则第 91条) 5.微波提取法:将茳芒与溶媒一同置微波中,利用微波使分子极化, 而使其成分溶出。 Correction page (Article 91) 5. Microwave extraction method: Put the awn in the microwave together with the solvent, and use the microwave to polarize the molecules to dissolve the components.
当本发明用于制备治疗糖尿病及改善其症状的药物时, 其口服或胃 肠夕卜给药, 均是安全的, 在口服情况下, 其可以任何常规形式给药, 如 散齐!]、 颗粒剂、 片剂、 胶囊剂、 丸剂、 溶液剂、 悬浮液、 糖浆、 口腔含 片、 舌下含片等; 当该药物肠胃外给药时, 可采取任何常规形式, 例如 注射剂 (如静脉内注射)、 软膏剂、 栓剂、 经皮给药、 吸入剂等。  When the present invention is used to prepare a medicament for treating diabetes and improving its symptoms, the oral or gastrointestinal administration is safe. In the case of oral administration, it can be administered in any conventional form, such as Sanqi! ], Granules, tablets, capsules, pills, solutions, suspensions, syrups, buccal tablets, sublingual tablets, etc .; When the drug is administered parenterally, it can take any conventional form, such as injections (such as Intravenous injection), ointments, suppositories, transdermal administration, inhalants, etc.
本发明制备治疗糖尿病及改善其症状的药物是由茳芒子或其水提取 物与固体或液体的赋形剂一起构成的, 这里使用的固体或液体的赋形剂 在本领域是众所周知的, 下面举几个具体例子, 散剂是内服的粉末剂, 它的赋形剂有乳糖、 淀粉、 浆糊精、 碳酸钙、 合成或天然硫酸铝、 氧化 镁、 硬脂酸镁, 碳酸氢钠、 干燥酵母等; 溶液剂的赋形剂有水、 甘油、 丙二醇、 单糖浆、 乙醇、 乙二醇、 聚乙二醇、 山梨糖醇等; 软膏剂的赋 形剂可以使用脂油, 含水羊毛脂、 凡士林、 甘油、 蜂腊、 木腊、 液体石 腊、 树脂、 高级腊等组合成的疏水剂或亲水剂。  The medicament prepared by the present invention for treating diabetes and improving its symptoms is composed of ramie or its water extract together with solid or liquid excipients. The solid or liquid excipients used herein are well known in the art, Here are some specific examples. Powder is an internal powder, and its excipients are lactose, starch, dextrin, calcium carbonate, synthetic or natural aluminum sulfate, magnesium oxide, magnesium stearate, sodium bicarbonate, dry Yeast, etc .; the excipients of the solution are water, glycerol, propylene glycol, monosyrup, ethanol, ethylene glycol, polyethylene glycol, sorbitol, etc .; the excipients of the ointment can be fatty oil, lanolin, petrolatum , Glycerin, beeswax, paraffin wax, liquid paraffin, resin, high-grade wax, etc.
有效物质的剂量可以根据服用方式, 病人的年龄和体重及病情严重 程度和其它类似的因素而改变,口服量为: 10.0-15.0mg/kg,每日二次服用: 注身寸 8.0-10.0mg/kg,每日一次。  The dosage of effective substance can be changed according to the way of taking, the age and weight of the patient and the severity of the disease and other similar factors. The oral dose is: 10.0-15.0mg / kg, twice daily. / kg, once a day.
本发明药物具有较好的降低血糖、治疗糖尿病及其改善症状的效果。 具体实施方式  The medicine of the invention has better effects of lowering blood sugar, treating diabetes and improving symptoms. detailed description
以下通过试验例来进一步阐述应用本发明制备所述药物的有益效 果, 这些试验例包括了药效学试验和临床疗效观察试验。  The beneficial effects of the medicament prepared by the present invention are further explained by the following test examples. These test examples include pharmacodynamic tests and clinical efficacy observation tests.
2 2
更正页(细则第 91条) 试验例 1 茳芒提取物对 Wistar大鼠高血糖动物模型的影响 1.1试验材料 Correction page (Article 91) Test example 1 Effect of burdock extract on hyperglycemic animal model in Wistar rats 1.1 Test materials
药品 茳芒提取物, 由吉林大学再生医学科学研究所新药研究室提 供, 批号: 20010708; 消渴丸由广州中药一厂生产, 批准文号: (1994) 第 11146号。  Drugs Mang Mang extract, provided by the Research Institute of New Drugs, Institute of Regenerative Medicine, Jilin University, batch number: 20010708; Xiaoke pills are produced by Guangzhou No. 1 Chinese Medicine Factory, approval number: (1994) No. 11146.
动物 wistar大鼠, 雌雄各半, 体重 195g -240g, 由吉林大学实验动 物部提供,质量合格证号: 医动字第 10-5110号; 主要试剂和仪器 链脲霉素 STZ 美国 sigma化学公司出品, 批号: 89H0604  Animal Wistar rats, male and female, weighing 195g-240g, provided by the Laboratory Animal Department of Jilin University, quality certificate number: Yidongzi No. 10-5110; main reagents and instruments streptozotocin STZ produced by the American sigma chemical company , Lot Number: 89H0604
血糖试条 北京怡成生物电子技术有限公司出品。 Blood glucose test strip produced by Beijing Yicheng Bioelectronic Technology Co., Ltd.
JPS-III型快速血糖测试仪 北京怡成生物电子技术有限公司出品。 JPS-III fast blood glucose tester produced by Beijing Yicheng Bioelectronic Technology Co., Ltd.
离心机 北京医用离心机厂, 型号: LDZ5— 2。 Centrifuge Beijing Medical Centrifuge Factory, Model: LDZ5-2.
全自动生化仪 日本日立公司出品, 型号: 日立 7170A型。  Fully automatic biochemical analyzer produced by Hitachi, Japan, Model: Hitachi 7170A.
1.2试验方法 1.2 Test method
试验条件与方法: Test conditions and methods:
自吉林大学动物部引入 Wistar大鼠后, 饲养于吉林大学基础医学院 动物室, 室温 22-25°C, 湿度 30-60%,饲料组成: 玉米面 39%、 豆饼面 25°/。、 麦糠面 14%、 高粱面 10%、 骨粉 2.5%、 鱼粉 5%、 酵母 3.5%、 添 加剂 1% 。  After the introduction of Wistar rats from the Animal Department of Jilin University, they were bred in the animal room of the Basic Medical College of Jilin University at room temperature 22-25 ° C, humidity 30-60%, feed composition: cornmeal 39%, bean cake noodle 25 ° /. , Wheat bran noodles 14%, sorghum noodles 10%, bone meal 2.5%, fish meal 5%, yeast 3.5%, and additives 1%.
取茳芒提取物药粉配成 5.2%(g/v)、 2.6%(g/v), 1.3%(g/v)大、 中、 小 三个剂量的供试药液。 消渴丸配成浓度为 20%(g/v)供试药液。  Take the mango extract powder to prepare 5.2% (g / v), 2.6% (g / v), 1.3% (g / v) large, medium and small doses of test solution. Xiaoke pill is formulated into a test solution with a concentration of 20% (g / v).
自吉林大学动物部引入 Wistar大鼠 110只,雌雄各半,在本室适应 1 周, 禁食不禁水 4小时后, 称体重、 测血糖、 作标记。 选择血糖值在正  110 Wistar rats, male and female, were introduced from the Animal Department of Jilin University. They were acclimatized for 1 week in the room, fasted for 4 hours, weighed, measured for blood glucose, and marked. Choose a positive blood glucose level
3 3
更正页(细则第 91条) 常范围内、状态好的 100只雌雄各半的大鼠做实验, 从中留 10只作为正 常对照组, 将 90只 Wistar大鼠用链脲霉素 STZ按 0.054g/kg造模型, 链 脲霉素 STZ用 0.05mol/L枸椽酸溶液 PH 4.5配成 2.0%的溶液,现用现配。 大鼠禁食不禁水 16小时后, 按体重腹腔一次注入链脲霉素 STZ药液。 第 8天禁食不禁水 4小时后, 测血糖, 其中血糖值大于 lOmmol/L为模 型成立。 与正常对照组比较有显著性差异 P<0.001。 将 54只高血糖模型 动物, 随机分为五组, 每组 10〜11只, 雌雄各组均分。 分组为: 正常对 照组、 模型组、 消渴丸组 2.0g/kg, 相当于临床用量的 4倍; 茳芒提取物 大剂量组 0.62g/kg、 中剂量组 0.31g/kg、 小剂量组 0.15g/kg, 相当于临床 用量的 8、 4、 2倍。 Correction page (Article 91) 100 male and female rats in the normal range and in good condition were tested, and 10 rats were left as the normal control group. 90 Wistar rats were modeled with streptozotocin STZ at 0.054 g / kg. The vegetarian STZ was formulated into a 2.0% solution with a 0.05 mol / L citric acid solution pH 4.5, and is now used. After fasting for 16 hours without fasting, rats were injected with streptozotocin STZ solution once intraperitoneally according to their weight. On the eighth day after fasting for 4 hours, the blood glucose was measured, and a blood glucose level of greater than 10 mmol / L was established as a model. Compared with the normal control group, there was a significant difference P <0.001. Fifty-four hyperglycemic model animals were randomly divided into five groups, with 10 to 11 animals in each group. The groups are: normal control group, model group, Xiaoke Wan group 2.0g / kg, which is equivalent to 4 times the clinical dosage; mango extract large dose group 0.62g / kg, medium dose group 0.31g / kg, low dose group 0.15g / kg, equivalent to 8, 4, or 2 times the clinical dosage.
模型组给水 10ml/kg, 各给药组均给予 10ml/kg供试药液。 每日上午 9时左右灌胃给药, 连续四周, 每周测血糖、 体重, 按新体重计算药量一 次。于给药第四周后处死动物, 取血测血常规、血液生化指标、血液流变 学和胰岛素含量,并取胰腺进行病理组织学检查。将各组所得结果以均值 ( )士标准差 (S)表示, 结果与模型组进行组间 t检验, 判断其显著性。  The model group was given 10 ml / kg of water, and each administration group was given 10 ml / kg of test solution. Gavage is administered around 9am every day for four consecutive weeks. Blood glucose and body weight are measured weekly, and the dose is calculated once based on the new weight. Animals were sacrificed after the fourth week of administration, blood tests were performed for blood routine, blood biochemical indicators, blood rheology and insulin content, and pancreas were taken for histopathological examination. The results obtained by each group are represented by the mean () ± standard deviation (S), and the results are compared with the model group to perform a t-test between the groups to determine their significance.
1.3试验结果  1.3 Test results
1.3.1对血糖的影响  1.3.1 Impact on Blood Sugar
给药后第三周茳芒提取物大剂量组、 中剂量组与模型组比较血糖明 显下降, P<0.05。 第四周茳芒提取物大、 中剂量组和消渴丸组血糖值均 降低, 与模型组比较, 具有明显统计学意义 P<0.05, 见表 1。  At the third week after administration, the blood glucose of the mango extract in the high-dose group, the middle-dose group and the model group significantly decreased, P <0.05. At the fourth week, the blood glucose levels of the large and medium doses of the mango extract were lowered. Compared with the model group, the blood glucose level was significantly statistically significant P <0.05, see Table 1.
4 4
更正页 (;细则第 91条) 动 1组剂 Correction page (; Article 91) Move 1 group
量别 S  Volume S
表 1 茳芒提取物对高血糖模型大鼠血糖值 (mmol/L)的影响( ΐ士 s) 正常对照组 ~~模型组 消渴丸组 大剂量组 中剂量组 小剂 ¾组 lOml/kg 2. Og/kg 0.62g/kg 0.31g/kg 0.15g/kg Table 1 Effect of Mangman extract on blood glucose value (mmol / L) in hyperglycemic model rats (ΐ 士 s) Normal control group ~~ Model group Xiaoke Wan group Medium dose group Small dose group ¾ Group 10ml / kg 2. Og / kg 0.62g / kg 0.31g / kg 0.15g / kg
10 8 9 10 9 8 给药前 6.11 ±0.53 17.52±2.40 17.22±3.22 17.04±3.34 17.10±2.63 16.34±3.32 一周 6.19±0.50 17.15±2.23 16.84±3.06 15.54±3.23 15.10±2.36 15.72±3.15 二周 6.12±0.41 15.85±3.02 14.57 ±3.02 13.59±2.60 14.06±2.53 15.18±3.23 三周 6.22:t0.31 14.05±3.52 11.97±2.53 10.93±2.58* 10.71±2, 72* 13.05±3.26 四周 5.89:t0.46 13.80±4.16 9.38±2.83* 9.07±2.78* 9.45 ±1.98* 11.71±3.53 与模型组比较 ,*P〈0.05 10 8 9 10 9 8 Before dosing 6.11 ± 0.53 17.52 ± 2.40 17.22 ± 3.22 17.04 ± 3.34 17.10 ± 2.63 16.34 ± 3.32 One week 6.19 ± 0.50 17.15 ± 2.23 16.84 ± 3.06 15.54 ± 3.23 15.10 ± 2.36 15.72 ± 3.15 Two weeks 6.12 ± 0.41 15.85 ± 3.02 14.57 ± 3.02 13.59 ± 2.60 14.06 ± 2.53 15.18 ± 3.23 Three weeks 6.22: t0.31 14.05 ± 3.52 11.97 ± 2.53 10.93 ± 2.58 * 10.71 ± 2, 72 * 13.05 ± 3.26 Four weeks 5.89: t0.46 13.80 ± 4.16 9.38 ± 2.83 * 9.07 ± 2.78 * 9.45 ± 1.98 * 11.71 ± 3.53 Compared with the model group, * P <0.05
试验伊 ί! 2 本发明药物治疗糖尿病患者的临床观察  Test Yi ί! 2 Clinical observation of the drug of the present invention in the treatment of diabetic patients
2.1—般资料 见表 2 表 2糖尿病患者饮用茳芒子后的情况 2.1—General information See Table 2 Table 2
Figure imgf000006_0001
Figure imgf000006_0001
5  5
更正页(细则第 91条) 2.2、 治疗结果 Correction page (Article 91) 2.2 Treatment results
2.2.1本发明的降糖效果极显著  2.2.1 The glucose-lowering effect of the present invention is extremely significant
从表 2可明显看出, 这 25名糖尿病患者经 28天饮用, 除 2名患者 出现腹泻和周身不适以外, 其余都有较明显降糖效果, 服用后和服用前 比较血糖值平均降低 2.0mmol/L, 重症患者降低 14.1mmol/L。 经 t测验 分析, t值 =3.161, 在自由度 N=N-1=23-1=22时, p=0.01的 t=2.819, 所 以降糖效果极显著。  It can be clearly seen from Table 2 that these 25 diabetic patients consumed it for 28 days. Except for 2 patients who had diarrhea and general discomfort, the others had a significant hypoglycemic effect. After taking and comparing the blood glucose level, the average blood glucose was reduced by 2.0mmol. / L, reduced by 14.1mmol / L in severe patients. After t-test analysis, the t-value = 3.161, and at the degrees of freedom N = N-1 = 23-1 = 22, p = 0.01 and t = 2.819, so the effect of reducing glucose is extremely significant.
2.2.2饮用时间越长, 效果越好 2.2.2 The longer you drink, the better the effect
2.2.2.1饮用一周显效情况如表 3 : 2.2.2.1 The results of one week of drinking are shown in Table 3:
饮用一周降糖效果分析  Analysis of hypoglycemic effect after drinking for a week
Figure imgf000007_0001
Figure imgf000007_0001
6 6
更正页(细则第 91条) 根据表 3进行 1:测验, 其结果: t=1.962, 当自由度 N-l=22-l=21时, ρ=0·05的 t=2.080, p=0,10的 t=1.721, 所以饮用一周虽有效果但不显著。 2.2.2.2饮用二周效果分析如表 4: Correction page (Article 91) Perform 1: test according to Table 3, the result is: t = 1.962, when the degree of freedom Nl = 22-l = 21, t = 2.080 at ρ = 0.05, and t = 1.721 at p = 0,10, so drink for one week Although effective, it is not significant. 2.2.2.2 The analysis of the effect of drinking for two weeks is shown in Table 4:
表 4 饮用二周降糖效果分析  Table 4 Analysis of hypoglycemic effect after drinking for two weeks
Figure imgf000008_0001
Figure imgf000008_0001
t测验结果, t=2.2637,当自由度 N=N-1=22-1=21时, p=0.05的 t=2.080, p=0.10的 t=2.831, 所以差异显著, 即效果明显。  t test result, t = 2.2637, when the degrees of freedom N = N-1 = 22-1 = 21, p = 0.05 t = 2.080, p = 0.10 t = 2.831, so the difference is significant, that is, the effect is obvious.
2.2.2.3饮用三周效果分析如表 5:  2.2.2.3 The effect analysis after drinking for three weeks is shown in Table 5:
更正页 (;细则第 91条) 表 5 饮用三周降糖效果分析 Correction page (; Article 91) Table 5 Analysis of hypoglycemic effect after drinking for three weeks
Figure imgf000009_0001
Figure imgf000009_0001
t测验结果, t=2.5043,当自由度 N=N-1=19-1=18时, p=0.05的 t=2.101 p=0.01的 t=2.878, 所以效果显著。  t test result, t = 2.5043, when the degree of freedom N = N-1 = 19-1 = 18, p = 0.05 t = 2.101 p = 0.01 t = 2.878, so the effect is significant.
2.2.2.4 饮用四周效果分析如表 6:  2.2.2.4 The analysis of the effects of drinking for four weeks is shown in Table 6:
8 8
更正页(细则第 91条) 患者 (An) 饮用前 饮用一周后 d Correction page (Article 91) Patient (An) One week before drinking d
血糖值 (X) 血糖值 (χ2) (X— X ) d— 7 Blood glucose level (X) Blood glucose level (χ 2 ) (X— X) d— 7
Al 11.0 6.7 4.3 2.566 6.584 Al 11.0 6.7 4.3 2.566 6.584
A2 15.8 12.3 3.5 1.766 3.118A2 15.8 12.3 3.5 1.766 3.118
A3 11.3 10.8 0.5 -1.234 1.522A3 11.3 10.8 0.5 -1.234 1.522
A4 9.7 8.8 0.9 -0.834 0.695A4 9.7 8.8 0.9 -0.834 0.695
A5 12.3 8.8 3.5 1.766 3.118A5 12.3 8.8 3.5 1.766 3.118
A6 7.9 7.0 0.9 -0.834 0.695A6 7.9 7.0 0.9 -0.834 0.695
A7 12.0 10.8 1.2 -0.534 0.285A7 12.0 10.8 1.2 -0.534 0.285
A8 7.2 7.5 -0.3 -2.034 4.137A8 7.2 7.5 -0.3 -2.034 4.137
A9 9.7 7.6 2.1 0.366 0.133A9 9.7 7.6 2.1 0.366 0.133
A10 5.9 6.7 -0.8 -2.534 6.421A10 5.9 6.7 -0.8 -2.534 6.421
All 10.2 9.8 0.4 -1.334 1.779All 10.2 9.8 0.4 -1.334 1.779
A12 6.8 6.3 0.5 -1.234 1.522A12 6.8 6.3 0.5 -1.234 1.522
A13 11.7 8.5 3.2 1.466 2.149A13 11.7 8.5 3.2 1.466 2.149
A14 8.9 5.9 3.0 1.266 1.602A14 8.9 5.9 3.0 1.266 1.602
A15 9.8 9.5 0.3 -1.434 2.056A15 9.8 9.5 0.3 -1.434 2.056
A16 7.2 6.5 0.7 -1.034 1.069A16 7.2 6.5 0.7 -1.034 1.069
A17 8.7 8.7 0 -1.734 3.006A17 8.7 8.7 0 -1.734 3.006
A18 10.8 10.2 0.6 -1.134 1.258A18 10.8 10.2 0.6 -1.134 1.258
A19 6.8 6.5 0.3 -1.434 1.602A19 6.8 6.5 0.3 -1.434 1.602
A20 8.9 8.8 0.1 -1.634 2.669A20 8.9 8.8 0.1 -1.634 2.669
A21 6.8 6.5 0.3 -1.434 1.602A21 6.8 6.5 0.3 -1.434 1.602
A22 8.4 7.8 0.6 -1.134 1.258A22 8.4 7.8 0.6 -1.134 1.258
A23 23.9 9.8 14.1 12.366 152.917 总和 231.7 (N=23 ) 186.8.1(N=23) 39.9 201.251 平均 10.07 "x 8.078 Έ( 1.734 A23 23.9 9.8 14.1 12.366 152.917 Total 231.7 (N = 23) 186.8.1 (N = 23) 39.9 201.251 Average 10.07 "x 8.078 Έ (1.734
经 t测验结果, t=3.161,当自由度 N=N-1=22-1=22时, p=0.05的 t=2.074, p=0.01的 t=2.819, 所以效果极显著。  According to the t test result, t = 3.161, when the degrees of freedom N = N-1 = 22-1 = 22, p = 0.05 t = 2.074, p = 0.01 t = 2.819, so the effect is extremely significant.
通过分析得出, 糖尿病患者饮用本发明, 饮用时间越长, 效果越明 显, 即饮用一周基本无效, 饮用两周显现降糖效果, 饮用三周降糖效果 显著, 饮用四周后降糖效果极显著。  According to the analysis, the diabetic patients drink the invention, the longer the drinking time, the more obvious the effect, that is, drinking for one week is basically ineffective, drinking for two weeks shows a hypoglycemic effect, drinking for three weeks has a significant hypoglycemic effect, and drinking for four weeks is extremely significant .
2.2.3患病年限与饮用效果分析 2.2.3 Analysis of disease duration and drinking effect
将表 1中 23名饮用本发明的糖尿病患者分成两组:患病 5年以上的 为一组, 患病 4年以下的为一组, 进行统计分析, 其结果-  The 23 diabetes patients drinking the present invention in Table 1 were divided into two groups: those who had been sick for more than 5 years as a group, and those who had been sick for less than 4 years as a group. Statistical analysis was performed, and the results were −
9 9
更正页(细则第 91条) .1、 患病 5年以上的效果分析如表 7 Correction page (Article 91) .1, the analysis of the effect for more than 5 years is shown in Table 7
表 7 患病 5年以上的饮用效果分析  Table 7 Analysis of drinking effects for more than 5 years
Figure imgf000011_0001
Figure imgf000011_0001
t测验结果, t=1.782,当自由度 N=N—1=13— 1=12时, p=0.05的 t=2.197, p=0.01的 t=1.782, 所以效果并不显著。  t test result, t = 1.782, when the degrees of freedom N = N—1 = 13—1 = 12, t = 2.197 at p = 0.05, and t = 1.782 at p = 0.01, so the effect is not significant.
2.2.3.2、 患病 4年以下的饮用效果分析如表 8 2.2.3.2. Table 8 shows the analysis of drinking effects for patients under 4 years of illness.
表 8 患病 4年以下的饮用效果分析  Table 8 Analysis of drinking effects after illness for 4 years
Figure imgf000011_0002
Figure imgf000011_0002
t测验结果, t=2.966,当自由度 N=N_ 1=10—1=9时, p=0.05的 t=2.262, p=0.01的 t=3.250,所以效果显著。  t test result, t = 2.966, when the degree of freedom N = N_ 1 = 10-1 = 9, p = 0.05 t = 2.262, p = 0.01 t = 3.250, so the effect is significant.
10 10
更正页(细则第 91条) 2.3结论 Correction page (Article 91) 2.3 Conclusion
1、 茳芒子对糖尿病患者降血糖有显著效果。  1. Amaranth has a significant effect on reducing blood sugar in patients with diabetes.
2、 糖尿病患者服用茳芒子两周即可显效, 四周效果显著。  2. Patients with diabetes can take two weeks to take effect, and the effect is obvious around four weeks.
3、 患病时间短 (4年以下) 比时间长 (5年以上) 服用茳芒子效果 好。  3. The disease is shorter (less than 4 years) longer than the time (more than 5 years).
以下通过实施例来进一步阐述本发明药物的制备。  The following examples further illustrate the preparation of the medicament of the present invention.
实施例 1  Example 1
茳芒子水提取物 2.0g,水 lOOOOml, 混合后装入 100 支瓶中, 每支 100ml, 含茳芒子提取物 20mg。  Mangosteen water extract 2.0g, water 1000ml, mixed into 100 bottles, each 100ml, containing 20mg of mangosteen extract.
实施例 2  Example 2
茳芒子 15.0g,药用淀粉 485g, 二者充分混合, 装胶囊, 制成 1000粒 胶囊, 每粒重 0.5g,含茳芒子 15mg。  15.0g of mangosteen and 485g of medicinal starch. The two are thoroughly mixed and filled into capsules to make 1000 capsules, each weighing 0.5g and containing 15mg of mangosteen.
11  11
更正页(细则第 91条)  Correction page (Article 91)

Claims

权 利 要 求 书  Request for Rights
、 茳芒在制备治疗糖尿病及改善其症状的药物中的应用。 The application of maggot in the preparation of medicine for treating diabetes and improving its symptoms.
、 茳芒水提取物在制备治疗糖尿病及改善其症状的药物中的应用 And hydrangea water extract in the preparation of medicine for treating diabetes and improving its symptoms
12 12
更正页(细则第 91条)  Correction page (Article 91)
PCT/CN2003/000995 2003-11-24 2003-11-24 Use of cassia sophera linn. for treating diabetes WO2005049057A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/CN2003/000995 WO2005049057A1 (en) 2003-11-24 2003-11-24 Use of cassia sophera linn. for treating diabetes
AU2003304545A AU2003304545A1 (en) 2003-11-24 2003-11-24 Use of cassia sophera linn. for treating diabetes
CNA2003801102572A CN1764466A (en) 2003-11-24 2003-11-24 Semen Cassiae Sopherae and extract thereof are in the treatment diabetes and improve application in its symptom medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2003/000995 WO2005049057A1 (en) 2003-11-24 2003-11-24 Use of cassia sophera linn. for treating diabetes

Publications (1)

Publication Number Publication Date
WO2005049057A1 true WO2005049057A1 (en) 2005-06-02

Family

ID=34596928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2003/000995 WO2005049057A1 (en) 2003-11-24 2003-11-24 Use of cassia sophera linn. for treating diabetes

Country Status (3)

Country Link
CN (1) CN1764466A (en)
AU (1) AU2003304545A1 (en)
WO (1) WO2005049057A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103550483B (en) * 2013-11-01 2015-11-25 王娟 A kind of preparation method for the treatment of the medicament of type 2 diabetes mellitus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1240115A (en) * 1999-05-18 2000-01-05 潘世全 Cassia sophera hypoglycemic thirst-quenching beverage and productive process

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1240115A (en) * 1999-05-18 2000-01-05 潘世全 Cassia sophera hypoglycemic thirst-quenching beverage and productive process

Also Published As

Publication number Publication date
AU2003304545A1 (en) 2005-06-08
CN1764466A (en) 2006-04-26

Similar Documents

Publication Publication Date Title
JP6271571B2 (en) Composition for maintaining intestinal microbiota equilibrium, process for producing the composition, and use of the composition
CN111110824B (en) Medicinal composition for strengthening body resistance and rescuing lung and application thereof
TWI777606B (en) Traditional chinese medicine formula flora capsule, preparation method and use thereof in preparing medicine for treating type 2 diabetes
WO2023005265A1 (en) Application of nucleotide mixture in preparation of formulations for preventing or alleviating senile sarcopaenia
WO2020015622A1 (en) Effect of combination of bifidobacterium and berberine on pre-diabetes and type 2 diabetes
WO2021164523A1 (en) Akkermansia muciniphila composition
EP3833370A1 (en) Compositions for use in the treatment of obesity
CN1403138A (en) Compound Chinese medicine prepn for treating urinary system infection and prostatitis and its prepn process
CN101618103B (en) Application of Chinese medicinal composition in preparing medicament for treating chronic glomerulonephritis
WO2005049057A1 (en) Use of cassia sophera linn. for treating diabetes
CN115919963A (en) Application of traditional Chinese medicine composition in preparation of medicine for treating novel coronavirus infection
WO2004032924A1 (en) The use of berberine as insulin sensitizer
JP7157253B2 (en) Chinese herbal composition for enema constipation, its preparation method and its use
CN102716128A (en) Pharmaceutical composition for treating asthma
CN103156865A (en) Application of L-arabinose in preparing medicines or health-care products
CN113813331A (en) Composition with throat clearing function and preparation method and application thereof
TWI698244B (en) Use of a combination of small-molecule fucoidan and fucoxanthin for preparing a composition for improving non-alcoholic fatty liver
CN110575505A (en) Medicine for treating acute bronchitis and acute attack of chronic bronchitis and preparation method and application thereof
Ajagun-Ogunleye et al. Hypoglycemic and high dosage effects of bidens pilosa in type-1 diabetes mellitus
CN112121056A (en) Application of composition of small-molecule fucoidin and fucoxanthin in preparation of composition for improving non-alcoholic fatty liver disease
CN1785205A (en) Dextran iron dispersing agent and its prepn. method
CN109394776B (en) Traditional Chinese medicine component formula for treating diffuse interstitial pulmonary fibrosis and application thereof
CN104491637B (en) It is a kind of to treat compound composite medicament of cough after common cold and preparation method and application
CN114558025B (en) Application of sessileflower acanthopanax root glycoside B in preparing medicine for lowering blood sugar of diabetes
CN111375020B (en) Medicine composition for treating diabetes, preparation method and application thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 20038B02572

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP